Details of the Drug Combination

General Information of Drug Combination (ID: DCJLJC7)

• Drug Combination Name: Insulin-glargine + Exenatide
• Indication: Type 2 Diabetes; Status: Phase 4 [1]
• Component Drugs:
  Insulin-glargine (DMR4HIW): Small molecular drug: 3D MOL is unavailable
  Exenatide (DMYHBKN): Small molecular drug: 3D MOL is unavailable

Molecular Interaction Atlas of This Drug Combination

Indication(s) of Insulin-glargine

Disease Entry	ICD 11	Status	REF
Diabetic complication	5A2Y	Approved	[2]
Non-insulin dependent diabetes	5A11	Approved	[3]
Malaria	1F40-1F45	Phase 3	[4]
Type-1 diabetes	5A10	Phase 3	[5]
Type-2 diabetes	5A11	Application submitted	[6]

Insulin-glargine Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Insulin (INS)	TTZOPHG	INS_HUMAN	Modulator	[9]

Insulin-glargine Interacts with 2 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Insulin receptor (INSR)	OTTY341H	INSR_HUMAN	Increases Phosphorylation	[10]
Insulin-like growth factor 1 receptor (IGF1R)	OTXJIF13	IGF1R_HUMAN	Increases Phosphorylation	[10]

Indication(s) of Exenatide

Disease Entry	ICD 11	Status	REF
Inflammation	1A00-CA43.1	Approved	[7]
Non-insulin dependent diabetes	5A11	Approved	[7]
Type-1/2 diabetes	5A10-5A11	Approved	[7]
Type-2 diabetes	5A11	Approved	[8]
Cardiovascular disease	BA00-BE2Z	Phase 3	[6]

Exenatide Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Glucagon-like peptide 1 receptor (GLP1R)	TTVIMDE	GLP1R_HUMAN	Binder	[11]

Exenatide Interacts with 1 DME Molecule(s)

DME Name	DME ID	UniProt ID	Mode of Action	REF
Dipeptidyl peptidase IV (DPP4)	DEKZQY6	DPP4_HUMAN	Metabolism	[12]

Exenatide Interacts with 1 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Albumin (ALB)	OTVMM513	ALBU_HUMAN	Affects Binding	[13]

References

• [1] ClinicalTrials.gov (NCT02455076) Exenatide Inpatient Trial: A Randomized Controlled Pilot Trial on the Safety and Efficacy of Exenatide (Byetta) Therapy for the Inpatient Management of Patients With Type 2 Diabetes
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7572).
• [3] Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA. 2022 Feb 8;327(6):534-545.
• [4] ClinicalTrials.gov (NCT02059161) A Study of the Safety and Efficacy of MK-1293 Compared to Lantus in Participants With Type 1 Diabetes Mellitus (T1DM) (MK-1293-003). U.S. National Institutes of Health.
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [6] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [7] Exenatide FDA Label
• [8] Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
• [9] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [10] IR and IGF-1R expression affects insulin induced proliferation and DNA damage. Toxicol In Vitro. 2017 Mar;39:68-74. doi: 10.1016/j.tiv.2016.11.011. Epub 2016 Nov 22.
• [11] Improved glycemic control and reduction of cardiometabolic risk factors in subjects with type 2 diabetes and metabolic syndrome treated with exenatide in a clinical practice setting. Diabetes TechnolTher. 2009 Jun;11(6):353-9.
• [12] In vitro metabolic stability of exendin-4: pharmacokinetics and identification of cleavage products. PLoS One. 2015 Feb 27;10(2):e0116805.
• [13] Biochemical, pharmaceutical and therapeutic properties of long-acting lithocholic acid derivatized exendin-4 analogs. J Control Release. 2010 Mar 3;142(2):206-13. doi: 10.1016/j.jconrel.2009.10.025. Epub 2009 Nov 10.